As described in my first article, the noninvasive prenatal testing ("NIPT") market is evolving at a pace that has rarely been seen in healthcare. This nascent market provides a compelling opportunity for investors able to see it through a fog of uncertainty. Sequenom (NASDAQ:SQNM) has maintained market leadership, since their launch of MaterniT21 in October 2011. The investment challenge: decipher the financial reporting in order to recognize the value proposition.
Supplement the financials with performance metrics. The objectives of financial reporting include providing:
· Valuable information to existing and prospective investors, employees, and creditors.
· Content to determine the economic resources and obligations of an enterprise.
· Reports to assess the amounts, timing and uncertainties of prospective...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|